Use of a Fluidized-Bed Bioreactor for the Production of Retroviral Vectors for Gene Therapy Applications

by James N. Warnock, PhD, Toby Price, PhD, Andrew Slade, PhD, and Mohamed Al-Rubeai, PhD
Volume 3, Issue 5 (September/October 2004)


Gene therapy is a promising medical technology that has the ability to treat inherited diseases. However, efficient and economical large-scale production of vectors is necessary to meet the potential patient demand. Several approaches have been evaluated for the mass production of retroviral vectors, including fixed-bed bioreactors, suspension cultures, and microcarrier cultures. In this article, we report on the use of a Cytopilot fluidized-bed bioreactor for the production of retroviral vectors from the human packaging cell line TEFLYRD…

Citation:
Warnock JD, Price T, Slade A, Al-Rubeai M. Use of a Fluidized-Bed Bioreactor for the Production of Retroviral Vectors for Gene Therapy Applications. BioProcess J, 2004; 3(5): 41-45.